Cingulate Inc. (NASDAQ:CINGW) Short Interest Update

Cingulate Inc. (NASDAQ:CINGW) was the recipient of a large decline in short interest in May. As of May 15th, there was short interest totaling 3,796 shares, a decline of 66.1% from the April 30th total of 11,190 shares. Based on an average trading volume of 16,655 shares, the short-interest ratio is presently 0.2 days.

Cingulate Stock Performance

Shares of CINGW stock traded up $0.01 during mid-day trading on Friday, hitting $0.04. 111,027 shares of the stock traded hands, compared to its average volume of 42,855. Cingulate has a 52-week low of $0.02 and a 52-week high of $0.18. The stock’s fifty day moving average is $0.03 and its two-hundred day moving average is $0.05.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.